
Shah Capital is reportedly pressing Novavax Inc. (NASDAQ:NVAX) to consider a sale of the biotech firm, citing continued struggles in the rollout of its COVID-19 vaccine.
• NVAX stock is showing exceptional strength. View the charts here.

Shah Capital is reportedly pressing Novavax Inc. (NASDAQ:NVAX) to consider a sale of the biotech firm, citing continued struggles in the rollout of its COVID-19 vaccine.
• NVAX stock is showing exceptional strength. View the charts here.